Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotech Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) (“Puma” or the “Company”) announced that Glass Lewis & Co., another leading independent proxy advisory firm, recommends that Puma shareholders revoke all consents on the BLUE Consent Revocation Card thereby rejecting the consent solicitation by Fredric Eshelman. The Company announced last week that ISS had made the same recommendation to Puma shareholders.

Back to news